Generation of human induced pluripotent stem cell-derived liver buds with chemically defined and animal origin-free media.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
21 10 2020
Historique:
received: 23 01 2020
accepted: 23 09 2020
entrez: 22 10 2020
pubmed: 23 10 2020
medline: 10 4 2021
Statut: epublish

Résumé

Advances in organoid technology have broadened the number of target diseases and conditions in which human induced pluripotent stem cell (iPSC)-based regenerative medicine can be applied; however, mass production of organoids and the development of chemically defined, animal origin-free (CD-AOF) media and supplements are unresolved issues that hamper the clinical applicability of these approaches. CD-AOF media and supplements ensure the quality and reproducibility of culture systems by lowering lot-to-lot variations and the risk of contamination with viruses or toxins. We previously generated liver organoids from iPSCs, namely iPSC-liver buds (iPSC-LBs), by mimicking the organogenic interactions among hepatocytes, endothelial cells (ECs), and mesenchymal cells (MCs) and recently reported the mass production of iPSC-LBs derived entirely from iPSCs (all iPSC-LBs), which should facilitate their large-scale production for the treatment of liver failure. However, in previous studies we used media originating from animals for differentiation except for the maintenance of undifferentiated iPSCs. Therefore, we developed a CD-AOF medium to generate all iPSC-LBs. We first developed a CD-AOF medium for hepatocytes, ECs, and stage-matched MCs, i.e., septum transversum mesenchyme (STM), in 2D cultures. We next generated all iPSC-LBs by incubating individual cell types in ultra-low attachment micro-dimple plates. The hepatic functions of all iPSC-LBs generated using the CD-AOF medium were equivalent to those of all iPSC-LBs generated using the conventional medium both in vitro and in vivo. Furthermore, we found that this CD-AOF medium could be used in several cell culture settings. Taken together, these results demonstrate the successful development of a CD-AOF medium suitable for all iPSC-LBs. The protocol developed in this study will facilitate the clinical applicability of all iPSC-LBs in the treatment of liver diseases.

Identifiants

pubmed: 33087763
doi: 10.1038/s41598-020-73908-1
pii: 10.1038/s41598-020-73908-1
pmc: PMC7578079
doi:

Substances chimiques

Culture Media 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17937

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK078392
Pays : United States

Références

Cell Rep. 2017 Dec 5;21(10):2661-2670
pubmed: 29212014
Nature. 2013 Jul 25;499(7459):481-4
pubmed: 23823721
Nature. 2017 Jun 22;546(7659):533-538
pubmed: 28614297
Nat Protoc. 2013 Jan;8(1):203-12
pubmed: 23288320
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12538-43
pubmed: 22802639
Sci Rep. 2017 Jan 30;7:41165
pubmed: 28134277
N Engl J Med. 2017 Mar 16;376(11):1038-1046
pubmed: 28296613
Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19240-5
pubmed: 22084120
Stem Cells. 2013 Mar;31(3):458-66
pubmed: 23193063
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Nat Protoc. 2014 Feb;9(2):396-409
pubmed: 24457331
Sci Rep. 2014 Jan 08;4:3594
pubmed: 24399248
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Hepatology. 2010 Jan;51(1):297-305
pubmed: 19998274
Nat Rev Genet. 2014 Feb;15(2):82-92
pubmed: 24434846
Nat Commun. 2012;3:1236
pubmed: 23212365
Nature. 2015 Oct 22;526(7574):564-8
pubmed: 26444236
Nature. 2013 Sep 19;501(7467):373-9
pubmed: 23995685
Nature. 2017 Aug 30;548(7669):592-596
pubmed: 28858313
Nat Biotechnol. 2010 Jun;28(6):611-5
pubmed: 20512123
Nature. 2011 Apr 7;472(7341):51-6
pubmed: 21475194
Cell Stem Cell. 2008 Nov 6;3(5):519-32
pubmed: 18983967
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Nat Biotechnol. 2007 Jun;25(6):681-6
pubmed: 17529971
Nat Methods. 2011 May;8(5):409-12
pubmed: 21460823
Transplant Proc. 2012 May;44(4):1127-9
pubmed: 22564643
Cell Stem Cell. 2013 May 2;12(5):520-30
pubmed: 23642363

Auteurs

Keisuke Sekine (K)

Division of Regenerative Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan. ksekine@ims.u-tokyo.ac.jp.
Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan. ksekine@ims.u-tokyo.ac.jp.

Shimpei Ogawa (S)

Research Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co., Inc., Kawasaki, 210-8681, Japan.

Syusaku Tsuzuki (S)

Division of Regenerative Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

Tatsuya Kobayashi (T)

Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

Kazuki Ikeda (K)

Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

Noriko Nakanishi (N)

Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

Kenta Takeuchi (K)

Division of Regenerative Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

Eriko Kanai (E)

Division of Regenerative Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

Yugo Otake (Y)

Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

Satoshi Okamoto (S)

Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

Tsuyoshi Kobayashi (T)

Research Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co., Inc., Kawasaki, 210-8681, Japan.

Takanori Takebe (T)

Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.
Advanced Medical Research Center, Yokohama City University, Yokohama, 236-0004, Japan.
Division of Gastroenterology, Hepatology and Nutrition, Developmental Biology, Center for Stem Cell and Organoid Medicine (CuSTOM), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229-3039, USA.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45229-3039, USA.

Hideki Taniguchi (H)

Division of Regenerative Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan. rtanigu@ims.u-tokyo.ac.jp.
Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan. rtanigu@ims.u-tokyo.ac.jp.
Advanced Medical Research Center, Yokohama City University, Yokohama, 236-0004, Japan. rtanigu@ims.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH